said, "Our research highlighted an additional mode of action for the treatment known as eprenetapopt opening up its potential to work in a broader group of acute myeloid leukemia (AML) andmyelodysplastic syndrome(MDS) patients.
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combination with chemotherapy. The drug is approved for use with a companion ...
Acute myelogenous leukemia (AML) is a rapidly progressive form of blood cancer that arises from immature myeloid cells. Traditional treatments, such as chemotherapy and bone marrow transplants, have had limited success in treating the disease, necessitating the development of novel therapeutic strategies...
Research led by Peter Mac and published inCancer Discoveryhas found a new combination therapy for acute myeloid leukemia (AML) that shows greater potency in a preclinical study than either drug used alone. AML is an aggressive type of blood cancer. When a patient has AML, immature abnormal whi...
A groundbreaking assay for detecting acute myeloid leukemia (AML) via KMT2A gene fusions promises to enhance diagnosis and treatment, representing a major leap in leukemia research. Researchers report that enhancing theaccuracyof detecting a particular molecular marker in leukemic cells can significantly ...
Acute myeloid leukemia (AML) also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.
Larson ML, Venugopal P. Clofarabine:a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother 2009;10:1353-1357.Larson ML, Venugopal P. Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert Opin Pharmacother. 2009;10(8):1353-7....
myeloid leukemia (CML) can already be tracked by the canonicalBCR-ABLfusion and sensitively detecting these fusions has revolutionized how CML is treated. For AML patients with oncogenic fusions driving their disease, theKMT2Afusion is a molecular marker that can be leveraged for sensitive ...
New Assay Could Revolutionize Detection and Treatment of Acute Myeloid Leukemia
The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the immense heterogeneity of this disease, treating it using a “one size fits all” approach is ineffective and only benefits a subset of patients. Instead, there is a shift towards more personalized treatment ...